SCLX:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.8183

Change

+0.02 (+2.29)%

Market Cap

USD 0.10B

Volume

0.59M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

-2.39 (-3.18%)

USD 233.63B
AMGN Amgen Inc

-0.46 (-0.15%)

USD 169.66B
SNY Sanofi ADR

-0.38 (-0.71%)

USD 136.24B
GILD Gilead Sciences Inc

+0.21 (+0.24%)

USD 108.60B
BIIB Biogen Inc

-2.29 (-1.25%)

USD 26.65B
GRFS Grifols SA ADR

+0.57 (+6.95%)

USD 7.00B
AMRN Amarin Corporation PLC

-0.01 (-1.62%)

USD 0.26B
MIRA MIRA Pharmaceuticals, Inc. Com..

+0.47 (+27.17%)

USD 0.03B
SCLXW Scilex Holding Company

+0.01 (+4.96%)

N/A

ETFs Containing SCLX

BTEC 0.00 % 0.42 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -59.89% 10% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.89% 10% F 6% D-
Trailing 12 Months  
Capital Gain -88.23% 11% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -88.23% 11% F 5% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -25.57% 22% F 14% F
Dividend Return -25.57% 22% F 14% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 36.86% 33% F 49% F
Risk Adjusted Return -69.36% 33% F 14% F
Market Capitalization 0.10B 22% F 38% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector